25.03
0.34 (1.38%)
| Penutupan Terdahulu | 24.69 |
| Buka | 24.97 |
| Jumlah Dagangan | 1,344,660 |
| Purata Dagangan (3B) | 2,628,553 |
| Modal Pasaran | 2,539,917,824 |
| Harga / Jualan (P/S) | 42.69 |
| Harga / Buku (P/B) | 2.66 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Operasi (TTM) | -1,596.87% |
| EPS Cair (TTM) | -4.61 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 0.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 14.08% |
| Nisbah Semasa (MRQ) | 8.81 |
| Aliran Tunai Operasi (OCF TTM) | -351.38 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -185.90 M |
| Pulangan Atas Aset (ROA TTM) | -19.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -38.04% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Beam Therapeutics Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.25 |
|
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.22% |
| % Dimiliki oleh Institusi | 98.07% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Mwg Management Ltd. | 30 Sep 2025 | 2,266,934 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 80.00 (HC Wainwright & Co., 219.62%) | Beli |
| Median | 46.00 (83.78%) | |
| Rendah | 35.00 (Evercore ISI Group, 39.83%) | Beli |
| Purata | 53.67 (114.42%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 25.94 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Evercore ISI Group | 24 Nov 2025 | 35.00 (39.83%) | Beli | 23.62 |
| HC Wainwright & Co. | 10 Oct 2025 | 80.00 (219.62%) | Beli | 26.32 |
| 15 Sep 2025 | 80.00 (219.62%) | Beli | 21.28 | |
| JP Morgan | 09 Oct 2025 | 46.00 (83.78%) | Beli | 27.87 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Nov 2025 | Pengumuman | Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference |
| 04 Nov 2025 | Pengumuman | Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates |
| 03 Nov 2025 | Pengumuman | Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |